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ARTICLE
Cancer Metabolism

Protein kinase D1 regulates metabolic switch in pancreatic
cancer via modulation of mTORC1
Sonam Kumari1, Sheema Khan1,2, Radhika Sekhri3, Hassan Mandil1, Stephen Behrman4, Murali M. Yallapu1,2,
Subhash C. Chauhan1,2 and Meena Jaggi1,2
BACKGROUND: Protein kinase D1 (PKD1) is a serine–threonine kinase that regulates various functions within the cell. Herein, we report
the signiﬁcance of PKD1 expression in glucose metabolism resulting in pancreatic cancer (PanCa) progression and chemo-resistance.
METHODS: PKD1 expression in PanCa was investigated by using immunohistochemistry. Functional and metabolic assays were utilised
to analyse the effect of PKD1 expression/knockdown on associated cellular/molecular changes.
RESULTS: PKD1 expression was detected in human pancreatic intraepithelial neoplasia lesions (MCS = 12.9; P < 0.0001) and pancreatic
ductal adenocarcinoma samples (MCS = 15, P < 0.0001) as compared with faint or no expression in normal pancreatic tissues (MCS =
1.54; P < 0.0001). Our results determine that PKD1 enhances glucose metabolism in PanCa cells, by triggering enhanced tumorigenesis
and chemo-resistance. We demonstrate that mTORC1 activation by PKD1 regulates metabolic alterations in PanCa cells. siRNA
knockdown of Raptor or treatment with rapamycin inhibited PKD1-accelerated lactate production as well as glucose consumption in
cells, which conﬁrms the association of mTORC1 with PKD1-induced metabolic alterations.
CONCLUSION: This study suggests a novel role of PKD1 as a key modulator of the glucose metabolism in PanCa cells accelerating
tumorigenesis and chemo-resistance. The remodelling of PKD1-dysregulated glucose metabolism can be achieved by regulation of
mTORC1 for development of novel therapeutic strategies.
British Journal of Cancer (2020) 122:121–131; https://doi.org/10.1038/s41416-019-0629-9

BACKGROUND
Pancreatic cancer (PanCa) is one of the deadliest diseases, and the
third most common cause of cancer-related deaths in the United
States.1 The lack of early detection, chemo-resistance and
increased metastasis contributes to the highly aggressive behaviour of this disease and poor survival rate.1 Therefore, it is
essential to investigate and comprehend mechanisms that lead to
the tumour aggressiveness and chemo-resistance in PanCa. One
such unique characteristic physiology of pancreatic tumours
includes a hostile and tumour microenvironment, which favours
biochemical and metabolic adaptations to facilitate pancreatic
tumour growth and metastasis. The metabolic alterations enable
cells to satisfy their bioenergetic needs by adapting to the
changing environments for survival, longevity and availability of
nutritional requirements.2 Cellular signalling empowers cancer
cells to acquire and process nutrients in a manner favourable to
proliferation than production of ATP.3 Through aerobic glycolysis,
cancer cells produce energy by converting glucose into lactate, in
the presence of oxygen, which results in enhanced synthesis of
lipids and nucleotides and stimulates growth and invasion. Herein,
we postulate that the identiﬁcation and strategic targeting of
molecules that regulate altered glucose metabolism can help in
the effective maintenance of the disease and development of
therapeutics.

Protein kinase D1 (PKD1), a serine–threonine kinase, is an
important modulator of several kinase signal transduction pathways.4 PKD1 belongs to the PKD family and is the most studied
protein kinase among the three family members (PKD1, PKD2 and
PKD3).4 Previous reports have suggested that PKD1 is involved in
pancreatic cancer pathogenesis,5,6 but the underlying signalling
mechanisms are largely unknown. Studies have suggested the role
of PKD1 in increasing pancreatic cancer proliferation and growth
rate through stimulation of NFκB, an important transcription factor
involved in various cellular mechanisms.7 PKD1 has also been
reported to be involved in the Notch pathway, being downstream
of KRAS, leading to pancreatic neoplasia.5 PKD1 expression
contributes to formation of preneoplastic lesions in a KRAS12Dinducible transgenic model, suggesting an essential role of PKD1
in the initiation and progression of PDAC.8 However, there are no
data available correlating PKD1 expression in human pancreatic
intraepithelial neoplasia lesions (PanINs), which are early pancreatic cancer lesions. Although PKD1 being upregulated in acinar cells
is known to regulate the duct formation leading to pancreatic
cancer initiation and growth,8 only little is known of how the PKD1
regulates cancer development. In addition, PKD1 acts as one of
the reactive oxygen species (ROS)- sensing molecule in the
tumour microenvironment, increases oxidative stress, ultimately
resulting in pancreatic cancer progression.6 Therefore, we were
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interested to further investigate the PKD1 expression during PDAC
development by using human PDAC tissue samples and molecular
changes inﬂuenced by PKD1 expression that may contribute to
pancreatic tumorigenesis. Our objective was to understand the
underlying molecular mechanisms involved in PKD1-induced
aberrant glucose metabolism and enhanced aggressiveness of
pancreatic cancer.
One of the most important pathways regulating metabolic
processes is the mTOR (mammalian target of rapamycin) pathway.9 mTOR is a serine/threonine kinase that exists as two
different complexes, mTORC1 and mTORC2. mTOR, in association
with Raptor and mLST8 forms mTORC1, regulates protein
translation, cell-cycle progression and metabolism.2 While mTOR
in association with Rictor (rapamycin-insensitive companion of
mTOR) and mSIN1 (stress-activated protein) forms mTORC2 and
regulates cell survival/glucose metabolism and cytoskeletal
remodelling.9 Rapamycin is known to inhibit mTORC1 activity
and promotes β-oxidation for anabolic storage pathways.
Thus, in this study, we present the expression proﬁle of PKD1 in
human PanINs (early–late), PDAC and chronic pancreatitis tissues
and determine its correlation with different tumour differentiation
status (well–poorly). In addition, this study suggests a novel role of
PKD1 in regulating glucose metabolism in pancreatic cancer,
which drives pancreatic tumorigenesis, chemo-resistance and
progression. This takes place in correlation with mTOR signalling,
wherein mTORC1 predominantly regulates PKD1-induced metabolic changes. PKD1 is aberrantly expressed in PanCa. The idea
was to identify novel mechanisms to develop newer therapeutic
strategies for this exceptionally difﬁcult cancer. By showing that
PKD1-mediated reprogramming of glucose metabolism regulates
the metabolic demands of malignant cells, we describe a novel
mechanism that is governed by PKD1 expression in PDAC. Brieﬂy,
our study prospects PKD1 as a novel molecular target in
pancreatic cancer for therapeutic intervention.
METHODS
Cell culture
All pancreatic cells (normal; HPNE and cancerous; HPAF-II, Panc-1,
Capan-1, MiaPaca, AsPC1 and BxPC3) used in this study were
obtained from ATCC. Among these, HPAF-II/BxPC3 are low PKD1
expressing, while Panc-1/AsPC1/Capan-1/MiaPaca are determined
high PKD1-expressing cells. All cells were maintained in DMEM/
F12 or RPMI media containing 10% foetal bovine serum in an
incubator at 37 °C temperature with 5% CO2. The normal human
pancreatic cell line, HPNE, was maintained in DMEM media. The
complete media, and the cell lines were maintained. The cells
were frequently investigated for mycoplasma growth and
contamination.
Procurement and scoring of human pancreatic cancer tissues for
analysis of PKD1 expression
Pancreatic cancer tissue microarray was procured from US Biomax
(# BIC14011a SL160) with chronic pancreatitis, early PanINs, late
PanINs and PDAC cores. Also, normal tissues were obtained from
Baptist Memorial Hospital (BMH), Memphis, TN. The scoring of the
PKD1 expression was performed as described earlier in detail.10
Stained slides were digitally scanned and analysed for
PKD1 staining at the University of Tennessee Health Science
Center (UTHSC) Pathology Department. Captured images were
independently analysed and scored by three reviewers, who were
kept blinded to the patient history. The intensity of immunoreactivity of PKD1 was graded on a 0–4 scale (0 for no staining, 1
for weak immunoreactivity, 2 for moderate immunoreactivity, 3 for
strong immunoreactivity and 4 for very strong immunoreactivity).
The percentage of cells positive for PKD1 immunoreactivity within
the tumour and normal tissue sections were scored as follows:
0–25% as 1, 26–50% as 2, 51–75% as 3 and 76–100% as 4. The

mean composite score (MCS) was determined by calculating an
average of the composite scores (intensity × percentage) of the
respective samples in each category.
Western blotting
The whole-cell lysates from pancreatic cancer cells were prepared
and used for investigating the changes in protein expression
through western blotting procedure, as described before.11,12
Brieﬂy, 40 µg of protein was loaded per well to perform SDS PAGE
followed by western blotting. The transfer of gels was done on
PVDF (polyvinylidene diﬂuoride) membrane and membranes were
blocked in either 5% nonfat dairy milk or 5% BSA (bovine serum
albumin) for 1 h followed by incubation with the primary
antibodies overnight at 4 °C. The primary antibodies with the
following catalogue numbers were procured from Cell Signaling
Technology: HIF-1α (3716), Glut-1 (12939), Ras (3965), KRAS-12D
(14429), eIF4e (9742S), peIF4e (9741S), 4EBP1 (9452S), p4EBP1
(2855S), mTOR (4517S), and p-mTOR (5536S). PKD1 antibody (sc639) was procured from Santa Cruz Biotechnology. β-actin
antibody was obtained from Sigma (A2228). The rabbit (4011)
and mouse (4021) secondary antibodies were purchased from
Promega company.
Immunoﬂuorescence
Immunoﬂuorescence was conducted as described earlier.13 Brieﬂy,
cells were ﬁxed, permeabilised and incubated overnight with
primary antibodies. The following day, the cells were incubated
with the respective secondary antibodies for 1 h, washed and
mounted. Further, the images were taken under a confocal
microscope at ×400 magniﬁcation (Zeiss 710, Germany).
Immunohistochemistry
Pancreatic cancer human tissue microarrays were obtained from
Baptist Memorial Hospital, Memphis, and were immunostained by
using antigen-retrieval method, as described earlier10 by using a
commercially available Biocare kit from Biocare Medical, CA, USA.
Brieﬂy, the tissue slides were deparafﬁnised, rehydrated, peroxidised and antigen retrieved. Further, the tissues were incubated
with primary antibodies overnight followed by addition of
secondary MACH4 Universal HRP mouse polymer (#M4U534H)
followed by staining with 3-diaminobenzidine (DAB) chromogen
(#DB801) and counterstaining with haematoxylin.
Transfection of cells
Pancreatic cancer cells having low PKD1 expression (HPAF-II and
BxPC3) were incubated in serum-free OPTI-MEM media overnight,
and transiently transfected with PKD1 expression plasmid and
control pEGFP by using Lipofectamine 2000 reagent. Following 6 h
of transfection, 10% serum-containing regular media was added
to the cells after removing the old media. The transfection
procedure was terminated after 48 h, and the cells were used for
further experiments.
Lactate assay/glucose assay
Lactate and glucose assays were performed by utilizing commercially available kits from Cayman Chemicals (lactate assay kit:
catalogue No. 600450 and glucose assay kit: catalogue No.
10009582). Cells were seeded as per the manufacturer’s instructions in the kit, and media of cells was used to determine the
amount of lactate production and glucose consumption upon
termination of the experiment at 24 and 48 h. Further, the
absorbance was recorded at the indicated wavelength, and
readings were analysed/calculated.
Cell migration assay
The cell migration assay was conducted by using Boyden chamber
plate.11,14,15 In total, 50,000 pancreatic cancer cells were seeded
on the top chamber of the 96-well plate in a serum-free media,
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and 250 µl of serum-containing media was added to the lower
chamber. L-Lactate (2 mM) or 2-deoxyglucose (2DG: 10 mM) were
added to the cells, which was followed by incubation for 18 h at
37 °C. Thereafter, the cells were ﬁxed with 4% paraformaldehyde,
stained with crystal violet and washed with water. The images of
cells were captured after complete drying of the plate.
Cell invasion assay
Cell invasion assay was performed by using Matrigel Invasion
Chambers from BD Biosciences.14 In total, 25,000 cells were
seeded in the chambers containing media without serum in the
upper chamber and complete media (10% FBS) in the lower one.
L-lactate (2 mM) or 2-deoxyglucose (10 mM) were added to the
cells, which was followed by incubation for 24 h at 37 °C. Further,
the cells were ﬁxed by methanol and stained by using crystal
violet. The plates were washed with water and left to dry, which
was followed by capturing images.
MTT assay/cell proliferation assay
MTT assay was performed in PKD1-expressing and null cells to
determine the effect of PKD1 in cell proliferation as described
before.11 Following 48 h, 20 µl of MTT reagent was added to the
cells. Then, 2 h after the addition of this reagent, 100 µl of
dimethyl-sulfoxide (DMSO) solution was added on top of the cells,
and the plate was subjected to vigorous shaking for another
10 min. Next, the absorbance was read at a wavelength of 570 nm,
the cell viability was calculated and the graph was plotted.
Colony formation assay
The pancreatic cancer cells were seeded in a 12-well plate (250
cells/well). The cells were subjected to both normoxic and hypoxic
conditions at the same time. For hypoxia experiments, the cells
were cultured at 37 °C with 5% CO2, 94% N2 and 1% O2 in a multigas incubator. The experiment was terminated after 7 days with
PBS wash, ﬁxed with 100% methanol and stained for 10 min with
crystal violet. The stain was carefully removed by thoroughly
washing with water, which was followed by air drying the plate
and capturing images by using a microscope. The colonies (>50
cells) were counted manually and plotted as described earlier.16
Quantitative polymerase chain reaction (qPCR)
RNA samples were isolated from various pancreatic cancer cells by
using Qiagen kit. The reaction was conducted as described
earlier.11 The concentration of samples was determined, and 2 µg
of RNA was reverse transcribed. The expression of genes (PKD1,
HIF-1α and Glut-1) was determined by precise primers through
real-time PCR experiment. GAPDH served as an internal control.
Statistical analysis
The signiﬁcance of the data in this paper was determined through
Student’s t test, and p-values below 0.05 were set to be statistically
signiﬁcant.
RESULTS
PKD1 expression is upregulated in human pancreatic cancer
tissues and cells
The expression proﬁle of PKD1 in human pancreatic cancer tissues
and normal samples (N = 45) was investigated by using immunostaining of PKD1 by immunohistochemistry. The samples
included early pancreatic intraepithelial neoplasia (PanINs), late
PanINs, pancreatic ductal adenocarcinoma (PDAC), normal pancreas and chronic pancreatitis. We evaluated the staining scores in
Mean Composite Score (MCS) by taking into account of the
average staining pattern. The MCS calculated for all tissues was
obtained by multiplying percentage intensity and the percentage
of tissue staining. Normal pancreatic tissues and chronic
pancreatitis tissues showed none or very faint PKD1 expression

(Fig. 1a i–ii). PKD1 expression was observed as early as in PanIN
lesion formation (Fig. 1a iiii–iv), whereas all of the stained PDAC
tissues showed moderate-to-high PKD1 expression (Fig. 1a v–vi).
Overall, PKD1 expression was signiﬁcantly higher (MCS: 15, P <
0.0001) in PDAC compared with normal pancreatic ductal
epithelium (Fig. 1a, b). PKD1 expression was predominantly
expressed all over the malignant area of the pancreatic cancer
tissues when compared with respect to grade (Fig. 1c), PanIN
lesions (Fig. 1d) and overall comparisons (Fig. 1e). Our results
clearly indicate that PKD1 expression effectively differentiated
PDAC from healthy controls and chronic pancreatitis. These results
further suggest that PKD1 is overexpressed in pancreatic cancers
and might have an oncogenic role in the malignant transformation of pancreatic cells. These results were in concordance with
the information available online in Oncomine database within two
different datasets (Segara and Badea).17,18 PKD1 was observed to
be highly expressed in pancreatic cancer tissues as compared with
normal/non-malignant pancreatic tissues (Supplementary Fig. S1).
We also investigated the expression level of PKD1 in a normal
pancreatic epithelial cell line (HPNE) and six pancreatic cancer
cells, which includes HPAF-II, Panc-1, Capan-1, MiaPaca, AsPC1 and
BxPC3 cells. Except HPAF-II and BxPC3, which showed less
expression of PKD1, most pancreatic cancer cells had high
expression of PKD1 at both mRNA (PCR, Fig. 2a) and protein
levels (immunoblotting and confocal immunoﬂuorescence, Fig. 2b,
c). We observed increased cytoplasmic expression of PKD1 in cells.
PKD1 contributes to tumorigenic characteristics via glucose
modulation
PKD1 overexpression or activation has been reported to facilitate
survival and proliferation of pancreatic cancer cells.19 In addition,
PKD1 is involved in transdifferentiation of pancreatic acinar cells
to a duct-like, pluripotent progenitor cell type (ADM, acinar-toductal metaplasia), leading to the initiation of pancreatic
cancer.8,20 Although studies suggest the oncogenic role of PKD1
in pancreatic cancer, the precise mechanisms directly inﬂuencing
the PKD1-induced tumorigenic characteristics are not elucidated.
These studies are essential to develop strategies to control
malignant transformation as well as increased tumour growth in
pancreatic cancer. To investigate the underlying molecular
mechanisms, we generated PKD1-overexpressing HPAF-II and
BxPC3 cells (having low PKD1) by using transient transfection. The
transient transfection was performed to observe the abrupt
molecular changes in the cell upon altering the PKD1 expression.
We observed an increase in the protein and mRNA levels of PKD1
expression in both the transfected cells, HPAF-II and BxPC3 by
using immunoblotting and PCR, respectively (Fig. 2d, e). We
observed an increase in the percentage of cell viability on
overexpression of PKD1 in both cells, HPAF-II and BxPC3 (Fig. 2f;
Supplementary Fig. S2A, B). In order to investigate the role of
PKD1 on glucose modulation in PanCa cells, glucose and lactate
assays were performed in PKD1-overexpressing cells, HPAF-II and
BxPC3. We observed signiﬁcantly (p < 0.05) higher upregulation of
glucose consumption and L-lactate production in PKD1overexpressing cells as compared with the control cells having
basal levels of PKD1 (Fig. 2g, h). Therefore, these results indicate
that PKD1 contributes to altered glucose metabolism of pancreatic
cancer cells. Our results further demonstrated increased migration
(Fig. 3a, b) and invasive (Fig. 3c, d) potential of HPAF-II and BxPC3
cells with PKD1 overexpression as compared with the control cells
with basal levels of PKD1. We further investigated if the changes in
glucose metabolism alter the enhanced tumorigenic characteristics of the cells on PKD1 overexpression. Our results demonstrate
that the proliferation (Fig. 3a, b), migration (Fig. 3c, d) and invasive
(Fig. 3e, f) potential of PKD1-overexpressing cells can be reduced
by inducing glucoprivic conditions by using 2-deoxyglucose or
potentiated by using lactate (2 mM), an end product of aerobic
glycolysis, in the cells. This further suggested the involvement of
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Fig. 1 PKD1 is highly expressed in human pancreatic cancer tissues. a Immunohistochemistry showing the expression of PKD1 protein in
normal (i), chronic pancreatitis (ii), early–late PanINs (iii and iv) and well–mod–poorly differentiated pancreatic cancer human tissues (v and vi).
b Boxplot representing quantiﬁcation and depiction of mean composite score in the overall normal and PDAC tissues for PKD1. c Mean
composite score in normal pancreas and different grades of pancreatic cancer tissues. d, e Comparison of mean composite score of normal
and malignant pancreatic tissues (magniﬁcation ×400)

glucose-accelerated mechanisms acquired by PanCa cells on PKD1
overexpression that accompanies enhanced tumorigenesis.
PKD1 leads to increased expression of signalling proteins that
trigger enhanced glucose metabolism
Alteration of metabolic processes requires the interplay between a
plethora of signalling events involving changes in the expression
of proteins. Glucose transporter-1 or GLUT1 is an important
protein that facilitates the transport of glucose across the plasma
membranes of cancer cells.21 Our results demonstrate that PKD1
overexpression in PanCa cells, HPAF-II and BxPC3, results in an
upregulation of protein as well as mRNA expression of GLUT1
(Fig. 4a–d). We also observed an increased protein (Fig. 4a, b) and
mRNA expression (Fig. 4c, d) of hypoxia-inducible factor or HIF-1α,
which has a role in metabolic switching and regulates glucose
metabolism.22 Therefore, we were interested to understand the
underlying molecular mechanisms that may be involved in
metabolic alterations accompanied by PKD1. Since mTOR signalling is widely reported to regulate HIF‑1α protein synthesis, we
particularly investigated mTOR pathway.23 mTOR is known as a
master regulator of growth and metabolic state of cells in
response to nutrients and extracellular stimuli. Interestingly, our
results clearly demonstrated that PKD1 overexpression enhances
the phosphorylation of mTOR (Fig. 4e, f). These results were
conﬁrmed upon silencing of endogenous PKD1 in Panc-1 cells

(having high PKD1 expression) that inhibited the aforementioned
events (Fig. 4g i and ii). In addition to the phosphorylation of
mTOR, endogenous expression of GLUT1 and HIF-1α was observed
to be reduced upon silencing endogenous PKD1 expression
(Fig. 4h), which suggests that PKD1-induced metabolic changes
may be inﬂuenced by mTOR phosphorylation. We next sought to
investigate whether the hypoxic environment has any effect on
PKD1-induced tumorigenic effects. BxPC3 and HPAF-II cells
cultured in a hypoxic environment displayed high clonogenicity
with formation of a greater number of colonies on PKD1
overexpression as compared with cells under normoxic environment (Supplementary Fig. S3).
PKD1 modulates glucose metabolism via mTORC1 activation
We set out to analyse whether PKD1-induced mTOR phosphorylation involves either mTORC1 or mTORC2 phosphorylation.
mTORC1 is known to modulate HIF-1α, which stimulates glycolysis
and glucose uptake. In order to elucidate the possible involvement of mTORC1, the major downstream effectors of mTORC1 are
the ribosomal S6 kinase (S6K) and the inhibitory eIF4E-binding
proteins (4E-BPs). mTORC1 activation phosphorylates S6K and 4EBP, which phosphorylates/activates downstream proteins involved
in initiation and elongation.24 We found that PKD1 overexpression
in PanCa cells results in enhanced phosphorylation of both the
effectors of mTORC1, pS6kinase and 4EBP1 (Fig. 5a). To our
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expectation, the silencing of endogenous PKD1 inhibited phosphorylation/activation of both the downstream effectors of
mTORC1. In addition to increased expression of pS6kinase and
4EBP1, an upregulation of p-AKT, a major effector of mTORC2, was
observed on PKD1 overexpression (Fig. 5a) suggesting the
activation of both the complexes of mTOR, mTORC1 and mTORC2.
Since mTORC1 is rapamycin sensitive, we investigated the effect of
PKD1 overexpression in the presence of rapamycin on the
phosphorylation of pS6kinase and mTOR-S2448, the major
phosphorylating domain of mTORC1. We observed that rapamycin
treatment prevented the increase in phosphorylation of both
pS6kinase and mTOR-S2448, indicating that mTORC1 is the main
effector of PKD1 (Fig. 5b). It is known that the kinase domain of
PKD1 is involved in the activation/phosphorylation of proteins.25
Therefore, in order to investigate whether the kinase region is
responsible for the increased activity/phosphorylation of mTOR,
BxPC3 cells were transfected with the PKD1 kinase dead domain
(PKD1-KD). Immunoblotting demonstrated inhibition in the
phosphorylation of mTOR-S2448 but not mTOR-S2481 (the major
phosphorylating domain of mTORC2) in cells transfected with

PKD1-KD. These results indicate two important conclusions: PKD1
directly phosphorylates mTOR-S2448 through its kinase domain
and mTORC1 being the downstream effector of PKD1 (Fig. 5c). We
next asked whether mTORC1 is directly involved in PKD1modulated glucose metabolism. For this, we investigated the
changes in the lactate production and glucose consumption in
PKD1- overexpressed cells in the presence or absence of
rapamycin. Our results clearly show that the PKD1-expressing
cells, in the presence of rapamycin, failed to increase lactate
production and glucose consumption (Fig. 5d). These effects were
conﬁrmed by using siRNA-mediated knockdown of Raptor or
Rictor, which are the determinants of the activation of mTORC1
and mTORC2, respectively,26 in the presence of PKD1 overexpression in cells. siRNA directed to Raptor but not Rictor,
inhibited the lactate production and glucose consumption
triggered by PKD1 (Supplementary Figs. S4 and 5E). No noticeable
changes were observed upon silencing Rictor. As Raptor is an
important component of mTORC1 complex,26 these results
indicated an obvious role of the mTORC1 pathway in the aberrant
metabolism induced by PKD1.
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PKD1 expression leads to drug resistance and its inhibition
sensitises gemcitabine response
High glucose accelerates cell proliferation in pancreatic cancer
cells and imparts chemo-resistance. Metabolic dysregulation is
one of the most common and recognisable features of cancer.
This facilitates the change in response to substrate availability due
to metabolic demands of the cell during proliferation, growth and
cell survival.11 Cancer/proliferating cells alter their ability to
metabolise biomolecules to meet increased energy demands. It
has been recognised that cancer cells increase glycolytic lactate
production independent of oxygen availability.27 In addition to
studies related to the role of PKD1 in glucose metabolism, we
were interested to investigate its effect on anticancer therapy.
Therefore, we wanted to investigate the effect of aberrant glucose
metabolism on the outcome of drug treatment in PanCa cells, and
whether response to drugs can be affected by excessive glucose
metabolism. Therefore, upon treatment of cells with lactate (2 µM,
48 h), we observed an increase in the viability of the cells and
resistance to gemcitabine treatment (Fig. 6a). Treatment of cells
with 2DG resulted in decreased viability and restored gemcitabine
sensitivity (Fig. 6b). In order to investigate the role of PKD1 in
chemo-resistance, we analysed the effect of PKD1 overexpression
on cell viability and gemcitabine resistance. As a result, we

observed an enhanced cell viability on PKD1 overexpression
(Fig. 6c i) and resistance to gemcitabine (Fig. 6c ii). Suppression of
PKD1, by using siRNA-mediated knockdown, reduced the cell
viability as well as gemcitabine resistance (Fig. 6d i and ii). In
addition, an induction of apoptosis by gemcitabine was observed
in the presence of 2DG as depicted by activation of apoptotic
protein, Bax, cleavage of PARP and inhibition of antiapoptotic Bcl2 (Fig. 6e). These outcomes indicate that expression of PKD1 in
pancreatic cancer cells results in chemo-resistance, which
attributes to the deregulated glucose metabolism, and its
suppression sensitises gemcitabine in pancreatic cancer cells
(Fig. 6f).
DISCUSSION
Excessive glucose metabolism is a signiﬁcant characteristic feature
of cancer. Pancreatic cancer cells require large amounts of glucose
for their survival. It leads to the fast growth and proliferation of the
cancer cells. Many signalling molecules are reported to play an
essential role in the aberrant metabolic processes, but further
studies are still required to develop effective treatment strategies
targeting glucose metabolism.28 Several reports indicate an
oncogenic role of the PKD1 protein in pancreatic cancer, but the
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mechanisms involved have not been sufﬁciently deﬁned.5,29
Therefore, in this study, we report a novel role of PKD1 in rewiring
of glucose metabolic network that drives favourable tumour
microenvironment and oncogenic signalling pathways in pancreatic cancer cells. This study demonstrates the role of PKD1 in
enhancing glucose metabolism of pancreatic cancer cells and
deﬁnes the underlying molecular mechanisms. In addition, this
study determines an important role of PKD1 in pancreatic cancer
chemo-resistance.
In this study, we demonstrate that PKD1 is highly expressed in
PanIN lesions and human PDAC as compared with less or no
expression in normal pancreatic tissues. This is the ﬁrst study to
our knowledge, which presents the expression proﬁle of PKD1 in
human PDAC. The oncogenic role of PKD1 in PanCa is growing
interest among the scientiﬁc community and several reports
suggest its role in pancreatic tumorigenesis.5,29,30 Herein, we
demonstrate a functional role of PKD1 in maintaining glucose
metabolism of PanCa cells and illustrate signalling mechanisms

that regulate the underlying molecular processes accompanying
altered glucose metabolism. Glucose transporter-1 (GLUT1)
mediates cellular transport of glucose required for anaerobic
metabolism in cancer cells.31 Oncogenic K-Ras mutation, a
signature event in pancreatic cancer, induces GLUT1 expression
resulting in anabolic glucose metabolism.32 Recent studies
suggest the association of KRAS mutations with the increased
PRKD1 promoter.8 Although a precise molecular mechanism of
how PKD1 induces GLUT1 expression, is not illustrated in this
paper, we speculate a functional link between the activation of
PKD1 with the oncogenic KRAS mutations induced by GLUT1
expression. Our studies suggest that PKD1 overexpression
enhances glucose uptake by increasing expression of GLUT1 in
PDAC cells. The increased GLUT1 expression enhances intracellular
glucose concentration due to augmented GLUT1-dependent
glucose uptake in cells, which accompanies extreme lactate
production and glucose consumption. Our results determine that
PKD1 overexpression leads to enhanced lactate production and
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glucose consumption while its knockdown reversed the effect.
The results are similar with the supplementation of cells with
lactate that potentiates the migration and invasion of PanCa cells.
While under glucoprivic conditions, in the presence of 2DG (a
glucose analogue that inhibits glycolysis),27,33 restores the PKD1induced tumorigenic effects. These data suggest that PKD1
promotes tumorigenesis by modulating glucose metabolism and
warrants further investigation for the underlying mechanisms. As
PKD1 was also observed to affect the expression of hypoxiainducible factor 1 (HIF-1), further investigations revealed hypoxic
environment being conducive to increased effects on cell growth,
as depicted by the ability of cells to colonize (Supplementary
Fig. S3) and warranted further investigation. However, these
results corroborated with recently published studies suggesting
that protein kinase D1 regulates HIF-1α in the human tongue
squamous cell carcinoma cells.34
mTOR is the conserved serine/threonine kinase that regulates
the proliferation and metabolism in cells. mTOR exists in two
distinct complexes with different protein components and downstream
substrates:
mTOR
complex
C1
and
C2.35
mTORC1 stimulates HIF-1α by regulating various enzymes for
glucose metabolism, including glucose transporters.36 This study
demonstrates that PKD1 phosphorylates/activates mTORC1 in
pancreatic cancer cells, as was depicted by the increased
activation/phosphorylation of its main effectors, pS6K and 4EBP1
on PKD1 overexpression (Fig. 5). In addition, the kinase dead
mutant of PKD1 did not enhance the phosphorylation/activation
of the major phosphorylating domain of mTORC1, mTOR-S2448.
The observed reduction in the phosphorylation of mTOR-S2448 in
cells expressing kinase mutant of PKD1 can be well explained with

the fact of a new phosphorylated protein not being produced,
while the accumulated protein being degraded with time (Fig. 5c).
These results indicate that PKD1 activity is necessary for mTORC1
activation. mTORC1 inactivation by rapamycin is known to be
critical for glucose metabolism.37,33 Rapamycin binds to the
FK506-binding protein of 12 kDa (FKBP12) and inhibits the activity
of mTORC1.38 Our ﬁndings demonstrate that mTORC1 activation
by PKD1 regulates metabolic alterations in pancreatic cancer cells.
These results were quite convincing as the treatment of rapamycin
inhibited accelerated lactate production as well as glucose
consumption due to PKD1 overexpression in cancer cells. In
addition, the signiﬁcance of mTORC1 activation in PKD1- induced
metabolic alterations was established upon knockdown of Raptor,
the main determinant of the activation of mTORC1, which
ultimately inhibited the metabolic changes associated with
PKD1. Since no signiﬁcant alterations of metabolic changes were
detected upon silencing Rictor, these results further conﬁrm the
association of mTORC1 with PKD1-induced metabolic alterations.
In other words, it can be stated that the promotion of glycolysis by
PKD1 can be regulated by mTORC1 suppression and this concept
can be utilised to develop novel therapeutic strategies.
Another major ﬁnding in this study demonstrates the role of
PKD1 in chemo-resistance. The results presented in this study
suggesting that PKD1 induces chemo-resistance due to aberrant
glucose metabolism, are signiﬁcant. In addition, we demonstrate
that altered glucose metabolism interferes with the sensitivity of
the drug and its outcomes in PanCa cells. Our data suggest that
PanCa cells become resistant to chemotherapeutic drugs in the
presence of enhanced glucose, which can be overcome by
depleting the glycolysis. An induction of apoptosis by gemcitabine
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was achieved in the presence of 2DG as depicted by activation of
apoptotic protein, Bax, cleavage of PARP and inhibition of
antiapoptotic Bcl-2. Our observations identify that modulation
of PKD1 expression can turn the PanCa cells sensitive to therapy.
This was indicated by using siRNA-mediated knockdown of PKD1
that rendered these cells sensitive to gemcitabine treatment.
In conclusion, we present the expression proﬁle of PKD1 in
human PanCa tissues and demonstrate that PKD1 is aberrantly
expressed in PanCa as compared with normal pancreatic tissues.

Our results suggest a novel role of PKD1 contributing to aberrant
glucose metabolism in pancreatic cancer cells, which accelerates
PanCa tumorigenesis and chemo-resistance. These interesting
ﬁndings strongly indicate that PKD1 can be explored as a novel
therapeutic target and as a biomarker, inhibition of which can
reduce pancreatic cancer progression and metastasis. The association of PKD1-induced mTOR pathway can be used as a therapeutic
strategy for the development of new drugs to target pancreatic
cancer. Moreover, as suggested by our results, PKD1 has a role in
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chemo-resistance owing to dysregulated glucose metabolism in
pancreatic cancer. Therefore, it can further be exploited to increase
the survival rate of pancreatic cancer patients. In conclusion, the
inhibition of PKD1 by using pharmacological agents and smallinterfering RNA/microRNA-mediated techniques can selectively
suppress pancreatic tumour growth and metastasis via inhibition
of glycolytic inﬂux in PDAC cells.
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